Journal of Cancer Research and Immuno-Oncology
Open Access

Carcinoma of the Vaginal Area in Humans with Versican Transcription

Kusumoto Seki^{* *}Correspondence: Kusumoto Seki, Department of Gynecology, Okayama University, Okayama, Japan, Email:

Author info »

Description

Expression of versican may facilitate tumour invasion and metastasis. Versican expressions in cervical cancer have, however, seldom ever been identified. Investigating versican expression in human cervical tumours was the goal of this investigation. In 174 cervical malignancies, immunohistochemically examined versican protein expression and examined the relationship to several clinicopathological characteristics, including patient prognosis. Patients who had lymph node metastases had considerably greater levels of stromal versican expression (p 0.0001). Patients with non-squamous cell cercinoma (p=0.0003), lymph-vascular space invasion (p=0.046), lymph node metastasis (p=0.009), and ovarian metastases (p=0.0001) had considerably higher levels of epithelial versican expression. High epithelial versican expression was identified by multivariate analysis as an independent predictive factor for disease-free survival. Versican enrichment of the tumour tissue may be related to cervical cancer development. Versican expression in cervical cancer patients may be a sign of a bad prognosis.

Critical stages in the development of malignant tumours, including cervical cancer, include tumour cell invasion and subsequent dissemination via the bloodstream and lymph arteries. It is evident that one of the key elements influencing how malignant cells behave is the tumour environment. For local cancer cell invasion and metastasis, the Extracellular Matrix (ECM) must be remodelled by changed expression of molecules involved in the functional network of cell-to-cell and cell-to-matrix interactions. One of the ECM's elements, proteoglycan, has the power to change how cells operate. The large aggregating Chondroitin Sulphate Proteoglycan (CSPG) family includes versican. Versican is structurally made up of a C-terminal G3 domain, an N-terminal G1 domain, and a Glycosaminoglycan (GAG) attachment region. Versican is produced by alternative splicing in at least four different isoforms, denoted V0, V1, V2, and V3. The biggest versican isoform, 3, 4, and 5 V0, has two GAG-binding domains known as the CS and CS domains. A CS domain is present in both the V1 isoform and the V2 isoform. Versican V3 lacks all possible GAG attachment sites and is only made up of the G1 and G3 domains. When a tissue is developing, versican is strongly expressed; however, after the tissue has reached maturity, its expression declines. Its expression is also increased while a wound is being repaired and when a tumour is expanding by reducing cell-ECM adhesion, a rise in versican expression in the ECM promotes local cancer invasion and metastasis. Versican expression has been shown to be associated with tumour growth in various types of malignant tumours. Although its expression in human cervical cancer has seldom been described, versican expression may thus promote tumour cell invasion and metastasis. Studies on versican protein was expressed in 174 cervical tumours. The link between it and different observable clinicopathological variables, including patient outcome, was then examined.

Fragments of sections

Clinical data and tissue samples: In this study, experiments were conducted on 174 individuals who had cervical cancer that was in stages IB to IIB according to the International Federation of Gynaecology and Obstetrics (FIGO). At the Okayama University Hospital's Obstetrics and Gynaecology Department, each of these patients had a radical hysterectomy and pelvic lymphadenectomy. At the time of surgery, tumour specimens were collected, fixed in 10%neutral-buffered formalin, and then embedded in paraffin. Each participant provided their informed permission.

Versican expression for stroma

Out of the total immunostaining of stromal versican in cervical tumours, 19 tumours (11%)had strong stromal staining, 35 tumours (20%) had moderate stromal staining, 36 tumours (21%) had mild stromal staining and 84 tumours (48%) had no stromal staining respectively. In instances with lymph node metastases, stromal versican expression was noticeably greater (p 0.0001).